Videos

Habte Yimer, MD, provides an overview of the ALPINE trial of zanubrutinib vs ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Lori J. Wirth, MD, provides an overview on the latest advancements in diagnosis of thyroid cancer.

Michiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.

Pedro Barata, MD, MSc, FACP, discusses tackling unmet needs in oncology at the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.

Dr. Hammers provides a perspective on the appropriateness of initial pembrolizumab + lenvatinib therapy based on guidelines.

Pedro Barata, MD, MSc, FACP, discusses the goals of the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.

Dr. Hammers discusses initial impressions of the case presentation, comparing it to typical advanced RCC, and reviewing risk factors.

Paula Rodriguez-Otero, MD, PhD, provides an overview of the phase 3 KarMMa-3 trial of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.

A phase 1, first-in-human study is evaluating a novel CAR T-cell therapy in patients with ovarian cancer at Moffitt Cancer Center.

Address the challenges and recommended approaches for managing the patient’s untreated brain metastases.

Discuss the role of molecular profiling and KRAS G12C testing in guiding treatment decisions of this case.

Raajit K. Rampal, MD, PhD, discusses some of the key takeaways from the 2023 American Society of Hematology Annual Meeting and what he believes holds promise for the space in 2024.

Eric Schroeder, MD, discusses how treatments for patients with ovarian cancer have evolved in recent years.

John Nakayama, MD, discusses the significance of the NRG GY018 study in endometrial cancer.

Tian Zhang, MD, and the Oncology Brothers offer comprehensive insights on the overall survival update for KEYNOTE-564 in renal cell carcinoma.

A review of interim findings from the AMBASSADOR study looking at adjuvant pembrolizumab in patients with muscle-invasive urothelial carcinoma.

Tian Zhang, MD, and the Oncology Brothers discuss the BRCAAway trial, which is investigating abiraterone, olaparib, or the combination in patients with metastatic castration-resistant prostate cancer.

Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.

Hatem Soliman, MD, discusses what unmet needs still have to be addressed in the HER2-positive breast cancer space.

Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.

Assess whether the initial therapy aligned with standard guidelines based on disease stage.

Provide an overview of the patient's presentation, diagnosis, and initial treatment plan.

Dr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.

Federico Albrecht, MD, discusses the challenging case of a 67-year-old heavy smoker who presented with small cell lung cancer.

Gary J. Schiller, MD, concludes with thoughts on the clinical implications of recent data presented at ASH 2023 on the myelodysplastic syndrome treatment landscape.

A hematologist/oncologist discusses a phase 1b/2 study investigating canakinumab in patients with myelodysplastic syndrome.

Virginia Kaklamani, MD, DSc, explains that key unmet needs in HR+/HER2- metastatic breast cancer include overcoming diverse mechanisms of endocrine resistance with genomic profiling and new agents like oral SERDs while managing side effects.

Virginia Kaklamani, MD, DSc, explains that managing adverse events like fatigue, GI toxicity, and musculoskeletal pain in patients with HR+/HER2- metastatic breast cancer using approaches such as exercise, anti-nausea medication, acupuncture, and supplements is key to meeting the dual treatment goals of prolonging life and maintaining quality of life.

Federico Albrecht, MD, discusses Miami Cancer Institute's specific protocol for hospitalized patients with small cell lung cancer.